Law

Reckitt Benckiser v. Tris Pharma - New Jersey Magistrate Finds No Trade Secret Misappropriation

By Owen J. McKeon, Ralph A. Dengler and Mitchell Boyarsky, Gibbbons

In a recent "not for publication" Memorandum Opinion and Order relating to Reckitt Benckiser's ("RB") over-the-counter cough syrup, Delsym® (dextromethorphan polistirex), United States Magistrate Judge Douglas E. Arpert of the District of New Jersey found that RB failed to establish trade secret misappropriation, unfair competition, and tortious interference with business expectations claimed against Tris Pharma, following a four-day bench trial.

Continue Reading

Law

Norman IP v. Lexmark: Post AIA Joinder and the Rule 42 Trump Card

By Frank A. Bruno and William A. Hector, Gibbons

In Norman IP Holdings, LLC v. Lexmark Int'l, Inc., a recent Eastern District of Texas decision, Chief District Judge Leonard Davis provided guidance on the application of Fed. R. Civ. P. 20 ("Rule 20") joinder and Fed. R. Civ. P. 42 ("Rule 42") consolidation in patent infringement cases post-enactment of the Leahy-Smith America Invents Act ("AIA"). Norman IP brought suit against Lexmark and others on September 15, 2011, one day before the AIA was signed into law. Norman IP later added an additional 23 defendants. The defendants filed a motion to dismiss for improper joinder or to sever, and Norman IP alternatively requested that any severed cases be consolidated under Rule 42. The Court granted defendants' motion to sever and issued an order consolidating the cases for pretrial issues excluding venue.

Continue Reading

Law

FTC Proposes Rules to Codify Reporting of Exclusive Patent Right Transfers in the Pharmaceutical Industry

By Anthony A. Dean, Gibbons

Is the sale or assignment of a patent reportable? The Hart-Scott Rodino Antitrust Improvements Act of 1976 ("HSR") and related rules  require that all acquisitions of voting securities or assets exceeding a threshold amount be reported to the Federal Trade Commission ("FTC"), as well as the Antitrust Division of the Department of Justice. The current threshold is $68.2 million.

Continue Reading

Law

Don't Forget About Those Seven Provisions of the AIA Effective September 16, 2012!

By Estelle J. Tsevdos and Jillian A. Centanni

Starting on September 16th, seven important provisions of the America Invents Act ("AIA") will take effect: inter partes review, post grant review, supplemental examination, third-party "preissuance submission," substitute statement in lieu of the inventor's oath/declaration, transitional program for covered business method patents, and citation of patent owner statements in a patent file. Not all of the provisions are applicable to every patent and/or patent application. So, it is important that one consults with patent counsel before taking action. Below are helpful takeaways and summaries of these key changes. More information can be found on the USPTO's website.

Continue Reading

Law

"Shield Act" Introduced to Thwart NPEs ...

By Ralph A. Dengler and Todd M. Nosher, Gibbons

We previously reported on the new 35 U.S.C. § 299 of the America Invents Act. This statute aims, inter alia, to reduce the ability of a patent owner to join multiple, unrelated defendants in a single action, which is a tactic often employed by non-practicing entities ("NPEs"), sometimes referred to as "patent trolls," who press defendants for nuisance value settlements.

Continue Reading

Law

Wrigley v. Cadbury: Judge Newman Emphasizes Commercial Success and Copying

By William A. Hector and R. Hain Swope, Gibbons

In WM. Wrigley Jr. v. Cadbury Adams USA, a recent Court of Appeals for the Federal Circuit decision related to chewing gum patents, Wrigley brought suit against Cadbury for infringement of its U.S. Patent Number 6,627,233 ("the '233 patent") claiming a chewing gum including a combination of menthol and a physiological cooling agent, WS-23. Cadbury counterclaimed against Wrigley for infringement of Cadbury's U.S. Patent Number 5,009,893 ("the '893 patent") claiming a chewing gum including menthol and a similar cooling agent entitled WS-3.

Continue Reading

GGI Logo 70x50px

GGI Geneva Group
International AG

Schaffhauserstrasse 550
P.O. Box 286
8052 Zurich
Switzerland

Contact

T: +41 44 2561818
F: +41 44 2561811
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.ggi.com